Product datasheet
Anti-IRAK4 antibody ab109335
2 Images
Overview
Product name
Anti-IRAK4 antibody
Description
Rabbit polyclonal to IRAK4
Tested applications
ICC/IF, WB
Species reactivity
Reacts with: Human
Immunogen
Synthetic peptide conjugated to KLH derived from within residues 100 - 200 of Human
IRAK4.Read Abcam's proprietary immunogen policy
Positive control
This antibody gave a positive signal in the following whole cell lysates: HeLa; Jurkat; THP1;
K562; Raw 264.7; MOLT4; U937. This antibody gave a positive result when used in the following
formaldehyde fixed cell lines: HeLa.
Properties
Form
Liquid
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or 80°C. Avoid freeze / thaw cycle.
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituent: PBS
Note: Batches of this product that have a concentration < 1mg/ml may have BSA added as a
stabilising agent. If you would like information about the formulation of a specific lot, please
contact our scientific support team who will be happy to help.
Purity
Immunogen affinity purified
Clonality
Polyclonal
Isotype
IgG
Applications
Our Abpromise guarantee covers the use of ab109335 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application
ICC/IF
Abreviews
Notes
Use a concentration of 5 µg/ml.
1
Application
Abreviews
WB
Notes
Use a concentration of 1 µg/ml. Detects a band of approximately 50 kDa
(predicted molecular weight: 51 kDa).
Target
Function
Required for the efficient recruitment of IRAK1 to the IL-1 receptor complex following IL-1
engagement, triggering intracellular signaling cascades leading to transcriptional up-regulation
and mRNA stabilization. Phosphorylates IRAK1.
Involvement in disease
Defects in IRAK4 are the cause of recurrent isolated invasive pneumococcal disease type 1
(IPD1) [MIM:610799]. Recurrent invasive pneumococcal disease (IPD) is defined as two
episodes of IPD occurring at least 1 month apart, whether caused by the same or different
serotypes or strains. Recurrent IPD occurs in at least 2% of patients in most series, making IPD
the most important known risk factor for subsequent IPD.
Defects in IRAK4 are the cause of IRAK4 deficiency (IRAK4D) [MIM:607676]. IRAK4 deficiency
causes extracellular pyogenic bacterial and fungal infections in otherwise healthy children.
Sequence similarities
Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. Pelle subfamily.
Contains 1 death domain.
Contains 1 protein kinase domain.
Anti-IRAK4 antibody images
ab109335 stained HeLa cells. The cells were
4% formaldehyde fixed (10 min) and then
incubated in 1%BSA / 10% normal goat
serum / 0.3M glycine in 0.1% PBS-Tween for
1h to permeabilise the cells and block nonspecific protein-protein interactions. The cells
were then incubated with the antibody
ab109335 at 5µg/ml overnight at +4°C. The
secondary antibody (green) was DyLight®
488 goat anti- rabbit (ab96899) IgG (H+L)
used at a 1/250 dilution for 1h. Alexa Fluor®
Immunocytochemistry/ Immunofluorescence -
594 WGA was used to label plasma
Anti-IRAK4 antibody (ab109335)
membranes (red) at a 1/200 dilution for 1h.
DAPI was used to stain the cell nuclei (blue)
at a concentration of 1.43µM.
2
All lanes : Anti-IRAK4 antibody (ab109335)
at 1 µg/ml
Lane 1 : HeLa (Human epithelial carcinoma
cell line) Whole Cell Lysate
Lane 2 : Jurkat (Human T cell lymphoblastlike cell line) Whole Cell Lysate
Lane 3 : THP1 (Human acute monocytic
leukemia cell line) Whole Cell Lysate
Lane 4 : K562 (Human erythromyeloblastoid
leukemia cell line) Whole Cell Lysate
Western blot - Anti-IRAK4 antibody (ab109335)
Lane 5 : RAW 264.7 (Mouse leukaemic
monocyte macrophage cell line) Whole Cell
Lysate
Lane 6 : MOLT4 (Human acute lymphoblastic
leukemia cell line) Whole Cell Lysate
Lane 7 : U937 (Human leukemic monocyte
lymphoma cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Secondary
Goat Anti-Rabbit IgG H&L (HRP)
preadsorbed (ab97080) at 1/5000 dilution
developed using the ECL technique
Performed under reducing conditions.
Predicted band size : 51 kDa
Observed band size : 50 kDa
Additional bands at : 22 kDa,42 kDa,74
kDa. We are unsure as to the identity of these
extra bands.
Exposure time : 2 minutes
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Our Abpromise to you: Quality guaranteed and expert technical support
Replacement or refund for products not performing as stated on the datasheet
Valid for 12 months from date of delivery
Response to your inquiry within 24 hours
We provide support in Chinese, English, French, German, Japanese and Spanish
Extensive multi-media technical resources to help you
We investigate all quality concerns to ensure our products perform to the highest standards
If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise,
3
please visit http://www.abcam.com/abpromise or contact our technical team.
Terms and conditions
Guarantee only valid for products bought direct from Abcam or one of our authorized distributors
4